330 related articles for article (PubMed ID: 36356603)
21. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
Venter WDF; Sokhela S; Simmons B; Moorhouse M; Fairlie L; Mashabane N; Serenata C; Akpomiemie G; Masenya M; Qavi A; Chandiwana N; McCann K; Norris S; Chersich M; Maartens G; Lalla-Edward S; Vos A; Clayden P; Abrams E; Arulappan N; Hill A
Lancet HIV; 2020 Oct; 7(10):e666-e676. PubMed ID: 33010240
[TBL] [Abstract][Full Text] [Related]
22. Counterfactual estimation of efficacy against placebo for novel PrEP agents using external trial data: example of injectable cabotegravir and oral PrEP in women.
Donnell D; Gao F; Hughes JP; Hanscom B; Corey L; Cohen MS; Edupuganti S; Mgodi N; Rees H; Baeten JM; Gray G; Bekker LG; Hosseinipour M; Delany-Moretlwe S
J Int AIDS Soc; 2023 Jun; 26(6):e26118. PubMed ID: 37363917
[TBL] [Abstract][Full Text] [Related]
23. Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among African adolescent girls and young women: a randomised, open-label, crossover trial.
Nair G; Celum C; Szydlo D; Brown ER; Akello CA; Nakalega R; Macdonald P; Milan G; Palanee-Phillips T; Reddy K; Tahuringana E; Muhlanga F; Nakabiito C; Bekker LG; Siziba B; Hillier SL; Baeten JM; Garcia M; Johnson S; McClure T; Levy L; Livant E; Jacobson C; Soto-Torres L; van der Straten A; Hosek S; Rooney JF; Steytler J; Bunge K; Parikh U; Hendrix C; Anderson P; Ngure K;
Lancet HIV; 2023 Dec; 10(12):e779-e789. PubMed ID: 37898146
[TBL] [Abstract][Full Text] [Related]
24. Epidemiological impact and cost-effectiveness of providing long-acting pre-exposure prophylaxis to injectable contraceptive users for HIV prevention in South Africa: a modelling study.
van Vliet MM; Hendrickson C; Nichols BE; Boucher CA; Peters RP; van de Vijver DA
J Int AIDS Soc; 2019 Dec; 22(12):e25427. PubMed ID: 31855323
[TBL] [Abstract][Full Text] [Related]
25. Updating the Adherence-Response for Oral Emtricitabine/Tenofovir Disoproxil Fumarate for Human Immunodeficiency Virus Pre-Exposure Prophylaxis Among Cisgender Women.
Anderson PL; Marzinke MA; Glidden DV
Clin Infect Dis; 2023 May; 76(10):1850-1853. PubMed ID: 36645796
[TBL] [Abstract][Full Text] [Related]
26. Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women.
Landovitz RJ; Donnell D; Clement ME; Hanscom B; Cottle L; Coelho L; Cabello R; Chariyalertsak S; Dunne EF; Frank I; Gallardo-Cartagena JA; Gaur AH; Gonzales P; Tran HV; Hinojosa JC; Kallas EG; Kelley CF; Losso MH; Madruga JV; Middelkoop K; Phanuphak N; Santos B; Sued O; Valencia Huamaní J; Overton ET; Swaminathan S; Del Rio C; Gulick RM; Richardson P; Sullivan P; Piwowar-Manning E; Marzinke M; Hendrix C; Li M; Wang Z; Marrazzo J; Daar E; Asmelash A; Brown TT; Anderson P; Eshleman SH; Bryan M; Blanchette C; Lucas J; Psaros C; Safren S; Sugarman J; Scott H; Eron JJ; Fields SD; Sista ND; Gomez-Feliciano K; Jennings A; Kofron RM; Holtz TH; Shin K; Rooney JF; Smith KY; Spreen W; Margolis D; Rinehart A; Adeyeye A; Cohen MS; McCauley M; Grinsztejn B;
N Engl J Med; 2021 Aug; 385(7):595-608. PubMed ID: 34379922
[TBL] [Abstract][Full Text] [Related]
27. Acceptability, safety, and patterns of use of oral tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis in South African adolescents: an open-label single-arm phase 2 trial.
Gill K; Johnson L; Dietrich J; Myer L; Marcus R; Wallace M; Pidwell T; Mendel E; Fynn L; Jones K; Wiesner L; Slack C; Strode A; Spiegel H; Hosek S; Rooney J; Gray G; Bekker LG
Lancet Child Adolesc Health; 2020 Dec; 4(12):875-883. PubMed ID: 33222803
[TBL] [Abstract][Full Text] [Related]
28. Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083.
Marzinke MA; Fogel JM; Wang Z; Piwowar-Manning E; Kofron R; Moser A; Bhandari P; Gollings R; Bushman LR; Weng L; Halvas EK; Mellors J; Anderson PL; Persaud D; Hendrix CW; McCauley M; Rinehart AR; St Clair M; Ford SL; Rooney JF; Adeyeye A; Chariyalertsak S; Mayer K; Arduino RC; Cohen MS; Grinsztejn B; Hanscom B; Landovitz RJ; Eshleman SH
Antimicrob Agents Chemother; 2023 Apr; 67(4):e0005323. PubMed ID: 36995219
[TBL] [Abstract][Full Text] [Related]
29. Preexposure Prophylaxis for the Prevention of HIV: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Chou R; Spencer H; Bougatsos C; Blazina I; Ahmed A; Selph S
JAMA; 2023 Aug; 330(8):746-763. PubMed ID: 37606667
[TBL] [Abstract][Full Text] [Related]
30. Pregnancy and neonatal safety outcomes of timing of initiation of daily oral tenofovir disoproxil fumarate and emtricitabine pre-exposure prophylaxis for HIV prevention (CAP016): an open-label, randomised, non-inferiority trial.
Moodley D; Lombard C; Govender V; Naidoo M; Desmond AC; Naidoo K; Mhlongo O; Sebitloane M; Newell ML; Clark R; Rooney JF; Gray G;
Lancet HIV; 2023 Mar; 10(3):e154-e163. PubMed ID: 36746169
[TBL] [Abstract][Full Text] [Related]
31. Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial.
Ramgopal MN; Castagna A; Cazanave C; Diaz-Brito V; Dretler R; Oka S; Osiyemi O; Walmsley S; Sims J; Di Perri G; Sutton K; Sutherland-Phillips D; Berni A; Latham CL; Zhang F; D'Amico R; Pascual Bernáldez M; Van Solingen-Ristea R; Van Eygen V; Patel P; Chounta V; Spreen WR; Garges HP; Smith K; van Wyk J
Lancet HIV; 2023 Sep; 10(9):e566-e577. PubMed ID: 37567205
[TBL] [Abstract][Full Text] [Related]
32. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.
Molina JM; Charreau I; Spire B; Cotte L; Chas J; Capitant C; Tremblay C; Rojas-Castro D; Cua E; Pasquet A; Bernaud C; Pintado C; Delaugerre C; Sagaon-Teyssier L; Mestre SL; Chidiac C; Pialoux G; Ponscarme D; Fonsart J; Thompson D; Wainberg MA; Doré V; Meyer L;
Lancet HIV; 2017 Sep; 4(9):e402-e410. PubMed ID: 28747274
[TBL] [Abstract][Full Text] [Related]
33. Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083.
Marzinke MA; Grinsztejn B; Fogel JM; Piwowar-Manning E; Li M; Weng L; McCauley M; Cummings V; Ahmed S; Haines CD; Bushman LR; Petropoulos C; Persaud D; Adeyeye A; Kofron R; Rinehart A; St Clair M; Rooney JF; Pryluka D; Coelho L; Gaur A; Middelkoop K; Phanuphak N; Cohen MS; Hendrix CW; Anderson P; Hanscom B; Donnell D; Landovitz RJ; Eshleman SH
J Infect Dis; 2021 Nov; 224(9):1581-1592. PubMed ID: 33740057
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial.
Gallant JE; Daar ES; Raffi F; Brinson C; Ruane P; DeJesus E; Johnson M; Clumeck N; Osiyemi O; Ward D; Morales-Ramirez J; Yan M; Abram ME; Plummer A; Cheng AK; Rhee MS
Lancet HIV; 2016 Apr; 3(4):e158-65. PubMed ID: 27036991
[TBL] [Abstract][Full Text] [Related]
35. HIV Preexposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate Among Cisgender Women.
Marrazzo J; Tao L; Becker M; Leech AA; Taylor AW; Ussery F; Kiragu M; Reza-Paul S; Myers J; Bekker LG; Yang J; Carter C; de Boer M; Das M; Baeten JM; Celum C
JAMA; 2024 Mar; 331(11):930-937. PubMed ID: 38427359
[TBL] [Abstract][Full Text] [Related]
36. Bone changes with candidate PrEP regimens containing tenofovir disoproxil fumarate and/or maraviroc and/or emtricitabine in US men and women: HPTN 069/ACTG A5305.
Brown TT; Yuhas K; Mayer KH; Landovitz RJ; Marzinke MA; Hendrix CW; Chen YQ; Klingman KL; Chege W; Mccauley MB; Gulick RM; Wilkin TJ
J Antimicrob Chemother; 2022 Feb; 77(2):500-506. PubMed ID: 34791296
[TBL] [Abstract][Full Text] [Related]
37. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.
Orkin C; DeJesus E; Ramgopal M; Crofoot G; Ruane P; LaMarca A; Mills A; Vandercam B; de Wet J; Rockstroh J; Lazzarin A; Rijnders B; Podzamczer D; Thalme A; Stoeckle M; Porter D; Liu HC; Cheng A; Quirk E; SenGupta D; Cao H
Lancet HIV; 2017 May; 4(5):e195-e204. PubMed ID: 28259777
[TBL] [Abstract][Full Text] [Related]
38. Sexual behavior and medication adherence in men who have sex with men participating in a pre-exposure prophylaxis study of combinations of Maraviroc, Tenofovir Disoproxil Fumarate and/or Emtricitabine (HPTN 069/ACTG 5305).
Mayer KH; Yuhas K; Amico KR; Wilkin T; Landovitz RJ; Richardson P; Marzinke MA; Hendrix CW; Eshleman SH; Cottle LM; Marcus C; Chege W; Rinehart AR; Rooney JF; Andrew P; Salata RA; Magnus M; Farley JE; Liu AY; Frank I; Ho K; Santana J; Stekler JD; Chen YQ; McCauley M; Gulick RM;
AIDS Behav; 2022 Dec; 26(12):4107-4114. PubMed ID: 35687192
[TBL] [Abstract][Full Text] [Related]
39. Using the adherence-efficacy relationship of emtricitabine and tenofovir disoproxil fumarate to calculate background hiv incidence: a secondary analysis of a randomized, controlled trial.
Glidden DV; Das M; Dunn DT; Ebrahimi R; Zhao Y; Stirrup OT; Baeten JM; Anderson PL
J Int AIDS Soc; 2021 May; 24(5):e25744. PubMed ID: 34021709
[TBL] [Abstract][Full Text] [Related]
40. Geographic Variation in Qualified Health Plan Coverage and Prior Authorization Requirements for HIV Preexposure Prophylaxis.
McManus KA; Fuller B; Killelea A; Strumpf A; Powers SD; Rogawski McQuade ET
JAMA Netw Open; 2023 Nov; 6(11):e2342781. PubMed ID: 37948076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
